A snapshot of lipid levels in the Republic of Ireland in 2017
- 33 Downloads
Abnormalities in blood lipid levels are causally linked with cardiovascular disease and pancreatitis. Data is limited regarding lipid abnormalities in Ireland.
As part of a cholesterol awareness campaign, we performed a pilot study of current lipid levels to preliminarily assess the extent and pattern of lipid abnormalities in Ireland.
Non-fasting, full lipid profiles and glucose measurements were performed in 259 people (32 on lipid-lowering medication and 225 untreated) using a validated Cholestech LDX machine. Untreated participants included 95 men and 130 women, aged 51 ± 16 years.
The mean ± SD, total, low-density lipoprotein (LDL), high-density lipoprotein cholesterol (HDL) and median(IQR) non-HDL cholesterol and triglyceride levels in untreated individuals were 5.0 ± 1.1, 2.8 ± 1.0, 1.5 ± 0.5 and 3.4 (2.8–4.3), 1.6 (1.0–2.3) mmol/l respectively. Glucose was 5.3 (4.8–5.8) mmol/l. Glucose > 7.8 mmol/l occurred in 10 individuals (4%). Using defined criteria for non-fasting lipid levels, 60% of participants had some form of lipid abnormality with a frequency of 47% having a total cholesterol > 5, 35% with LDL > 3.0, 26% with HDL < 1.0/1.2, 33% with triglycerides > 2.0 and 32% with non-HDL cholesterol > 3.9 mmol/l. Three individuals had untreated LDL > 5 mmol/l (i.e. a ratio of 1:75 of those tested) and eight people had HDLc < 0.7 (1:28) and four had triglyceride above 7.3 mmol/l (1:56).
This pilot study reveals significant lipid abnormalities which require further larger more detailed lipid studies to assess the true burden of lipid abnormalities in Ireland. Cascade screening and genetic testing of relatives of those with severe lipid abnormalities should be considered.
KeywordsCholesterol Ireland Lipid genetic disorders Lipids Non-fasting Screening
We are grateful to the Communications department, CEO and staff of Tallaght Hospital for their assistance with the cholesterol campaign and lipid testing approval. We acknowledge Alere/Abbot Laboratories for the provision of test cassettes and Cholestech LDX machines used to complete the lipid testing on site. We also appreciate the support from the various venues used for cholesterol testing. Special thanks to the Meath Foundation and Sanofi Ireland for their ongoing support for the Advanced Lipid Management And Research (ALMAR) Centre at Tallaght hospital and the Irish Lipid Network. The public awareness campaign would not have been possible without generous coverage from numerous national and local newspapers and radio stations as well as RTE news.
- 1.Ference BA, Ginsberg HN, Graham I, Ray KK, Packard CJ, Bruckert E, Hegele RA, Krauss RM, Raal FJ, Schunkert H, Watts GF, Borén J, Fazio S, Horton JD, Masana L, Nicholls SJ, Nordestgaard BG, van de Sluis B, Taskinen MR, Tokgözoğlu L, Landmesser U, Laufs U, Wiklund O, Stock JK, Chapman MJ, Catapano AL (2017) Low-density lipoproteins cause atherosclerotic cardiovascular disease. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel. Eur Heart J 38:2459–2472. https://doi.org/10.1093/eurheartj/ehx144 CrossRefGoogle Scholar
- 4.Chapman MJ, Ginsberg HN, Amarenco P, Andreotti F, Borén J, Catapano AL, Descamps OS, Fisher E, Kovanen PT, Kuivenhoven JA, Lesnik P, Masana L, Nordestgaard BG, Ray KK, Reiner Z, Taskinen MR, Tokgözoglu L, Tybjærg-Hansen A, Watts GF, for the European Atherosclerosis Society Consensus Panel (2011) Triglyceride-rich lipoproteins and high-density lipoprotein cholesterol in patients at high risk of cardiovascular disease: evidence and guidance for management. Eur Heart J 32:1345–1361CrossRefGoogle Scholar
- 8.Toskes PP (1990) Hyperlipidaemic pancreatitis. Gastroenterol Clin N Am 19(4):783–791Google Scholar
- 9.Sniderman AD, Williams K, Contois JH et al., A meta-analysis of low-density lipoprotein cholesterol, non-high-density lipoprotein cholesterol, and apolipoprotein B as markers of cardiovascular risk. Circ Cardiovasc Qual Outcomes 2011;4:337–345.Google Scholar
- 10.Voight BF, Peloso GM, Orho-Melander M, Frikke-Schmidt R, Barbalic M, Jensen MK, Hindy G, Hólm H, Ding EL, Johnson T, Schunkert H, Samani NJ, Clarke R, Hopewell JC, Thompson JF, Li M, Thorleifsson G, Newton-Cheh C, Musunuru K, Pirruccello JP, Saleheen D, Chen L, Stewart AFR, Schillert A, Thorsteinsdottir U, Thorgeirsson G, Anand S, Engert JC, Morgan T, Spertus J, Stoll M, Berger K, Martinelli N, Girelli D, McKeown PP, Patterson CC, Epstein SE, Devaney J, Burnett MS, Mooser V, Ripatti S, Surakka I, Nieminen MS, Sinisalo J, Lokki ML, Perola M, Havulinna A, de Faire U, Gigante B, Ingelsson E, Zeller T, Wild P, de Bakker PIW, Klungel OH, Maitland-van der Zee AH, Peters BJM, de Boer A, Grobbee DE, Kamphuisen PW, Deneer VHM, Elbers CC, Onland-Moret NC, Hofker MH, Wijmenga C, Verschuren WMM, Boer JMA, van der Schouw YT, Rasheed A, Frossard P, Demissie S, Willer C, Do R, Ordovas JM, Abecasis GR, Boehnke M, Mohlke KL, Daly MJ, Guiducci C, Burtt NP, Surti A, Gonzalez E, Purcell S, Gabriel S, Marrugat J, Peden J, Erdmann J, Diemert P, Willenborg C, König IR, Fischer M, Hengstenberg C, Ziegler A, Buysschaert I, Lambrechts D, van de Werf F, Fox KA, el Mokhtari NE, Rubin D, Schrezenmeir J, Schreiber S, Schäfer A, Danesh J, Blankenberg S, Roberts R, McPherson R, Watkins H, Hall AS, Overvad K, Rimm E, Boerwinkle E, Tybjaerg-Hansen A, Cupples LA, Reilly MP, Melander O, Mannucci PM, Ardissino D, Siscovick D, Elosua R, Stefansson K, O'Donnell CJ, Salomaa V, Rader DJ, Peltonen L, Schwartz SM, Altshuler D, Kathiresan S (2012 Aug 11) Plasma HDL cholesterol and risk of myocardial infarction: a Mendelian randomisation study. Lancet 380(9841):572–580CrossRefGoogle Scholar
- 12.Rohatgi A, Khera A, Berry JD et al., HDL cholesterol efflux capacity and incident cardiovascular events. N Engl J Med 2014;371:2383–2393.Google Scholar
- 13.Nordestgaard B, Chapman M, J, Humphries S, for the European Atherosclerosis Society Consensus Panel et al (2013) Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population:guidance for clinicians to prevent coronary heart disease Consensus Statement of the European Atherosclerosis Society. EHJ 34:3478–3490. https://doi.org/10.1093/eurheartj/eht 273
- 14.Lipids, lipoproteins, and apolipoproteins as risk markers of myocardial infarction in 52 countries (the INTERHEART study): a case-control study. Lancet. 2008 ;372(9634):224–33.Google Scholar
- 15.Kabir Z, Perry I, Critchley J, O’Flaherty M, Capewell S, Bennett K (2013) Modelling coronary heart disease mortality declines in the Republic of Ireland 1985–2006. Int J Cardiol 2013 Oct 3;168(3):2462–2467.Google Scholar
- 16.Central Statistics Office (2013) Vital statistics and fourth quarter and yearly summary 2012. Central Statistics Office, Stationery Office, DublinGoogle Scholar
- 18.Murphy C, Shelley E, O'Halloran AM, Fahey T, Kenny RA (2017) Failure to control hypercholesterolaemia in the Irish adult population: cross-sectional analysis of the baseline wave of The Irish Longitudinal Study on Ageing (TILDA). Ir J Med Sci 186:1009–1017. https://doi.org/10.1007/s11845-017-1590-3. CrossRefGoogle Scholar
- 19.Farzadfar F, Finucane MM, Danaei G, Pelizzari PM, Cowan MJ, Paciorek CJ, Singh GM, Lin JK, Stevens GA, Riley LM, Ezzati M (2011) National, regional, and global trends in serum total cholesterol since 1980: systematic analysis of health examination surveys and epidemiological studies with 321 country-years and 3.0 million participants. Lancet 377(9765):578–586CrossRefGoogle Scholar
- 20.M. Carey, C Markham P Gaffney G Boran V Maher Validation of a point of care lipid analyser using a hospital based reference laboratory Dec 2006 Irish Journal of Medical ScienceGoogle Scholar
- 21.Friedewald WT, Levy RI, Fredrickson DS (1972) Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 18:499–502Google Scholar
- 22.Nordestgaard BG, Langsted A, Mora S, Kolovou G, Baum H, Bruckert E, Watts GF, Sypniewska G, Wiklund O, Boren J, Chapman MJ, Cobbaert C, Descamps OS, von Eckardstein A, Kamstrup PR, Pulkki K, Kronenberg F, Remaley AT, Rifai N, Ros E, Langlois M, for the European Atherosclerosis Society (EAS) and the European Federation of Clinical Chemistry and Laboratory Medicine (EFLM) Joint Consensus Initiative (2016) European Atherosclerosis Society (EAS) and the European Federation of Clinical Chemistry and Laboratory Medicine (EFLM) Joint Consensus Initiative. Fasting Is Not Routinely Required for Determination of a Lipid Profile: Clinical and Laboratory Implications Including Flagging at Desirable Concentration Cutpoints-A Joint Consensus Statement from the European Atherosclerosis Society and European Federation of Clinical Chemistry and Laboratory Medicine. Clin Chem 62(7):930–946. https://doi.org/10.1373/clinchem.2016.258897 CrossRefGoogle Scholar
- 23.Irish College of General Practitioners—A Practical Guide to Integrated Type 2 Care 2016Google Scholar
- 24.UK Heart Survey NHS The information centre for health and social care (2011) Health Survey for England 2011 Health, social care and lifestyles, Summary of key findings. Department of Health, LondonGoogle Scholar
- 25.Morgan K, McGee H, Watson D et al., (2007) SLAN 2007: Survey of lifestyle, attitudes & nutrition in Ireland. Main report. Department of Health and Children, DublinGoogle Scholar
- 27.Leahy S, O’Halloran A, O’Leary N, Healy M, McCormack M, Kenny R, O’Connell J (2015) Prevalence and correlates of diagnosed and undiagnosed type 2 diabetes mellitus and pre-diabetes in older adults: findings from the Irish Longitudinal Study on Ageing (TILDA). Diabetes Res Clin Pract 110:241–249CrossRefGoogle Scholar
- 29.Murphy C, Bennett K, Fahey T, Shelley E, Graham I, Kenny RA (2015) Statin use in adults at high risk of cardiovascular disease mortality: cross-sectional analysis of baseline data from The Irish Longitudinal Study on Ageing (TILDA). BMJ Open 5:e008017. https://doi.org/10.1136/bmjopen-2015-008017 CrossRefGoogle Scholar
- 30.Kotseva K, De Bacquer D, De Backer G, On Behalf of the Euroaspire Investigators Lifestyle and risk factor management in people at high risk of cardiovascular disease et al (2016) A report from the European Society of Cardiology European Action on Secondary and Primary Prevention by Intervention to Reduce Events (EUROASPIRE) IV cross-sectional survey in 14 European regions. Eur J Prev Cardiol 23(18):2007–2018. https://doi.org/10.1177/2047487316667784 CrossRefGoogle Scholar
- 33.Khera AV, Won HH, Peloso GM, Lawson KS, Bartz TM, Deng X, van Leeuwen EM, Natarajan P, Emdin CA, Bick AG, Morrison AC, Brody JA, Gupta N, Nomura A, Kessler T, Duga S, Bis JC, van Duijn CM, Cupples LA, Psaty B, Rader DJ, Danesh J, Schunkert H, McPherson R, Farrall M, Watkins H, Lander E, Wilson JG, Correa A, Boerwinkle E, Merlini PA, Ardissino D, Saleheen D, Gabriel S, Kathiresan S (2016 Jun 7) Diagnostic Yield and Clinical Utility of Sequencing Familial Hypercholesterolemia Genes in Patients with Severe Hypercholesterolemia. J Am Coll Cardiol 67(22):2578–2589CrossRefGoogle Scholar